Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits
of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads …

Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …

Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been
studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable …

Apoptosis resistance is to a large extent a major obstacle leading to chemotherapy failure
during cancer treatment. Bypassing the apoptotic pathway to induce cancer cell death is …

Therapeutic monoclonal antibodies targeting immune checkpoints (ICPs) have changed the
treatment landscape of many tumors. However, response rate remains relatively low in most …

Cancer immunotherapies, such as immune checkpoint blockade and chimeric antigen
receptor (CAR) T cell therapy, have transformed clinical oncology. However, limited patient …

Objective This article will outline the link between the immune system and cancer, and
provide a historical timeline of immunotherapy developmental milestones. Data Sources …

Simple Summary Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is the first
oncolytic viral immunotherapy to be approved for the local treatment of unresectable …